Use of Lumisight in conjunction with the Lumicell fluorescent imaging system was found to be safe and effectively guide breast cancer surgeries.

The agency on March 5 issued separate alerts detailing quality challenges at imaging providers in Michigan, California and Texas. 

This is a Class I recall, which means using the device “may cause serious injuries or death.” However, the FDA emphasized that this is a correction and not a product removal.

President Joe Biden signed a funding bill worth $460 billion on March 9, but it only included partial relief for cardiologists, cardiac surgeons and other cardiology professionals. 

The American Medical Association issued a response, noting the “significant financial disruption for physician practices” during the weeks-long shutdown. 

President Biden signed the spending bill into law March 9, averting a government shutdown, following its passage in the Senate. 

Have hospitals really taken a step backward along their march toward price transparency? Or is the watchdog outfit making the claim playing fast and loose with the facts?

The FDA made a special announcement about its decision, describing the news as "a major advance for public health."